Artificial intelligence vision-screening company Eyenuk (Woodland Hills, Calif.) said it has launched an AI-powered diagnostic service for diabetic retinopathy.
The EyeScreen service connects primary care/diabetes care clinics with eye care specialists and is designed to increase access to diabetic retinopathy screening, reduce wait times, and improve patient compliance on receiving necessary screenings, according to the company. By offering diabetic retinopathy screening in the clinic, any physician can identify diabetic retinopathy sooner and begin intervention to improve patient outcomes and reduce the incidence of vision loss, Eyenuk said.
The EyeScreen Service is a novel approach to disease detection that uses independent, unbiased interpretation by a human expert and a validated, autonomous AI system that does not rely on humans interpreting complex assistive AI reports. After the retinal images are independently assessed by both the AI disease detection system and specialist human graders separately, an ICD-10 compliant report is sent to the physician. In the event that the AI and human graders disagree, the images are adjudicated by another highly experienced human expert.
“The EyeScreen service is our unique take on combining expert human grading with a validated autonomous AI system, allowing users to benefit from the best of both worlds,” said Eyenuk CEO Kaushal Solanki in a prepared statement. “We are thrilled to empower physicians with the ability to screen patients in clinic, without requiring dilation, for the best chance of early DR detection.”
